Business
-
Freeman Technology has moved to a new, larger facility in the Tewkesbury Business Park in Gloucestershire, UK. The new building includes office, laboratory, and manufacturing areas; additional space for expansion is available. Freeman has been… Read more . . .
-
On September 5, a ceremony in Tehran marked the occasion as Iran officially phased out CFC-based metered dose inhalers (MDIs) in accordance with the Montreal Protocol, becoming the first country in the Asia-Pacific region to… Read more . . .
-
UK drug delivery device company Bespak, a division of Consort Medical, says that it will develop a nasal delivery device “for a major unnamed global pharmaceutical company.” The contract, Bespak’s first for a nasal device,… Read more . . .
-
According to the FDA’s latest update on the ongoing acetylcysteine inhalation solution shortage, all of American Regent/Luitpold’s product is still on back order due to “manufacturing delays,” and the company is still unable to estimate… Read more . . .
-
The United States Court of Appeals has upheld a patent for Fortical calcitonin nasal spray held by Unigene Laboratories. Fortical, a bioequivalent of Novartis’s Miacalcin, is marketed in the US by Unigene subsidiary Upsher-Smith for… Read more . . .
-
Aegis Therapeutics has received US Patent No. 7,998,927 for stabilized formulations of GLP-1 peptide analogs that can be delivered by a variety of different routes, including intranasal. All currently available GLP-1 formulations, which can control… Read more . . .
-
Massacheusetts biotech company Pulmatrix has secured $14 million in additional funding from its existing investors, including Polaris Venture Partners, 5AM Ventures, Arch Venture Partners, and Novartis Venture Fund, bringing its total to $60 million. Terry… Read more . . .
-
The United States Patent and Trademark Office (USPTO) has issued US Patent No. 7,994,197, titled “Method of Therapeutic Administration of DHE to Enable Rapid Relief of Migraine while Minimizing Side Effect Profile,” to MAP Pharmaceuticals for its… Read more . . .
-
Akela Pharma is looking for a buyer for its Taifun fentanyl development program after Teikoku Seiyaku returned Japanese rights to the product. The dry powder inhaler (DPI) was being developed for the treatment of breakthrough… Read more . . .
-
According to news reports, the US Federal Bureau of Investigation (FBI) has raided the San Diego, California headquarters of vaccine developer NexBio and removed papers. FBI agent Darrell Foxworth is quoted as saying that the… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden
October 21-October 22: MVIC Symposium, Lund, Sweden
October 28-October 30: Deutches Aerosol Therapie Symposium (DATS), Marburg, Germany
November 10-November 11: Rescon Europe 2026, Porto, Portugal